Century Therapeutics Management
Management criteria checks 1/4
Century Therapeutics' CEO is Brent Pfeiffenberger, appointed in Dec 2023, has a tenure of 1.08 years. total yearly compensation is $3.24M, comprised of 1.5% salary and 98.5% bonuses, including company stock and options. directly owns 0.39% of the company’s shares, worth $293.59K. The average tenure of the management team and the board of directors is 1.1 years and 3.7 years respectively.
Key information
Brent Pfeiffenberger
Chief executive officer
US$3.2m
Total compensation
| CEO salary percentage | 1.5% |
| CEO tenure | 1.1yrs |
| CEO ownership | 0.4% |
| Management average tenure | 1.1yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101
Jun 20Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely
Mar 06
Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy
Feb 01We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate
Oct 23Century Therapeutics receives IND clearance for allogeneic cell therapy candidate
Aug 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$130m |
| Jun 30 2024 | n/a | n/a | -US$131m |
| Mar 31 2024 | n/a | n/a | -US$133m |
| Dec 31 2023 | US$3m | US$50k | -US$137m |
Compensation vs Market: Brent's total compensation ($USD3.24M) is above average for companies of similar size in the US market ($USD643.82K).
Compensation vs Earnings: Insufficient data to compare Brent's compensation with company performance.
CEO
Brent Pfeiffenberger
1.1yrs
Tenure
US$3,235,011
Compensation
Mr. Brent Pfeiffenberger, Pharm D., MBA, has been Chief Executive Officer and Director of Century Therapeutics, Inc. since December 04, 2023. He served as Chief Operating Officer at Neogene Therapeutics, I...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.1yrs | US$3.24m | 0.39% $ 293.6k | |
| Chief Development Officer | 3.8yrs | US$1.71m | 0.10% $ 77.1k | |
| Chief Technology & Manufacturing Officer | 1.1yrs | US$2.59m | 0.40% $ 306.2k | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Scientific Officer | less than a year | no data | 0.17% $ 131.1k | |
| Senior VP of General Counsel | no data | no data | no data | |
| Chief People Officer | no data | no data | no data | |
| Senior VP of Cell Engineering | 1.7yrs | no data | no data | |
| Senior VP & Head of Clinical Development | 2yrs | no data | no data | |
| SVP, Head of Corporate Affairs & Strategy | no data | no data | no data | |
| Senior VP of Finance & Operations and Secretary | no data | no data | 0.33% $ 247.4k |
1.1yrs
Average Tenure
56yo
Average Age
Experienced Management: IPSC's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.1yrs | US$3.24m | 0.39% $ 293.6k | |
| Independent Director | 3.9yrs | US$170.65k | 0.12% $ 88.2k | |
| Independent Chairman of the Board | 6yrs | US$197.40k | 0.58% $ 440.5k | |
| Independent Director | 2.3yrs | US$159.40k | 0% $ 0 | |
| Independent Director | 3.7yrs | US$161.90k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$169.65k | 0.0059% $ 4.5k | |
| Independent Director | 3.9yrs | US$168.40k | 0% $ 0 | |
| Independent Director | 3.7yrs | US$165.90k | 0% $ 0 |
3.7yrs
Average Tenure
60.5yo
Average Age
Experienced Board: IPSC's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 06:48 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Century Therapeutics, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Charlie Yang | BofA Global Research |
| William Maughan | Canaccord Genuity |